Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia

Archives of Pharmacal Research

Volumn 36, Issue 6, 2013, Pages 651-659

  Park, Eun Ji ^a   Amatya, Sarmila ^b   Kim, Myung Sun ^a   Park, Jong Hoon ^c   Seol, Eunyoung ^c   Lee, Heeyong ^c   Shin, Young Hee ^b   Na, Dong Hee ^a  

^a Kyungpook National University   (South Korea)

^b Kyungsung University   (South Korea)

^c Peptron Inc   (South Korea)

Author keywords

Antipsychotic drugs; Long acting formulation; Olanzapine pamoate; Paliperidone palmitate; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ANGIOPEPTIN; ARIPIPRAZOLE; BUSERELIN ACETATE; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DROPERIDOL; EXENDIN 4; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; ILOPERIDONE; LEUPRORELIN; LONG ACTING DRUG; LURASIDONE; MINOCYCLINE; NALTREXONE; NEUROLEPTIC AGENT; OCTREOTIDE; OLANZAPINE; PALIPERIDONE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIOXANTHENE DERIVATIVE; TRIPTORELIN; ZIPRASIDONE; ZOTEPINE;

ACROMEGALY; AKATHISIA; ALCOHOLISM; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPHORIA; ESTERIFICATION; HUMAN; IN VITRO STUDY; MAINTENANCE THERAPY; NEGATIVE SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIODONTAL DISEASE; PROSTATE CANCER; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SUSTAINED DRUG RELEASE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 84878998624     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0105-7     Document Type: Review

References (48)

1. Altamura, A.C.; F. Sassella, A. Santini, C. Montresor, S. Fumagalli, and E. Mundo. 2003. Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 63: 493-512. (Pubitemid 36337728)
2. Baweja, R.; K. Sedky, and S. Lippmann. 2012. Long-acting antipsychotic medications. Current Drug Targets 13: 555-560.
3. Bishara, D. 2010. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatric Disease and Treatment 6: 561-572.
4. Cha, Y.; and C.G. Pitt. 1988. A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules. Journal of Controlled Release 8: 69-78.
5. Choi, J.S.; K. Seo, and J.W. Yoo. 2012. Recent advances in PLGA particulate systems for drug delivery. Journal of Pharmaceutical Investigation 42: 155-163.
6. Chue, P.; and J. Chue. 2012a. A review of paliperidone palmitate. Expert Review of Neurotherapeutics 12: 1383-1397.
7. Chue, P.; and J. Chue. 2012b. A review of olanzapine pamoate. Expert Opinion on Pharmacotherapy 13: 1661-1670.
8. Eerdekens, M.; I. Van Hove, B. Remmerie, and E. Mannaert. 2004. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Research 70: 91-100. (Pubitemid 38916632)
9. Ereshefsky, L.; and C.A. Mascarenas. 2003. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Journal of Clinical Psychiatry 64: 18-23. (Pubitemid 37523324)
10. Ereshefsky, L.; and E. Mannaert. 2005. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: Potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs in R&D 6: 129-137. (Pubitemid 40994250)
11. Fleischhacker, W.W. 2009. Second-generation antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry 52: S29-S36.
12. Froemming, J.S.; Y.W. Lam, M.W. Jann, and C.M. Davis. 1989. Pharmacokinetics of haloperidol. Clinical Pharmacokinetics 17: 396-423. (Pubitemid 20020153)
13. Harrison, T.S.; and K.L. Goa. 2004. Long-acting risperidone: A review of its use in schizophrenia. CNS Drugs 18: 113-132. (Pubitemid 38293596)
14. Horacek, J.; V. Bubenikova-Valesova, M. Kopecek, T. Palenicek, C. Dockery, P. Mohr, and C. Höschl. 2006. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20: 389-409. (Pubitemid 43763739)
15. Hu, Z.; Y. Liu, W. Yuan, F. Wu, J. Su, and T. Jin. 2011. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Colloids and Surfaces B: Biointerfaces 86: 206-211.
16. Iqbal, M.M.; A. Rahman, Z. Husain, S.Z. Mahmud, W.G. Ryan, and J.M. Feldman. 2003. Clozapine: A clinical review of adverse effects and management. Annals of Clinical Psychiatry 15: 33-48. (Pubitemid 36723639)
17. Janssen, P.A.; C.J. Niemegeers, F. Awouters, K.H. Schellekens, A.A. Megens, and T.F. Meert. 1988. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 244: 685-693. (Pubitemid 18076615)
18. Kane, J.M. 2006. Utilization of long-acting antipsychotic medication in patient care. CNS Spectrums 11: 1-7.
19. Klose, D.; F. Siepmann, K. Elkharraz, and J. Siepmann. 2008. PLGA-based drug delivery systems: Importance of the type of drug and device geometry. International Journal of Pharmaceutics 354: 95-103. (Pubitemid 351410450)
20. Knox, E.D.; and G.L. Stimmel. 2004. Clinical review of a long-acting, injectable formulation of risperidone. Clinical Therapeutics 26: 1994-2002. (Pubitemid 40353609)
21. Kramer, M.; R. Litman, D. Hough, R. Lane, P. Lim, Y. Liu, and M. Eerdekens. 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. International Journal of Neuropsychopharmacology 13: 635-647.
22. Leucht, S.; T.R. Barnes, W. Kissling, R.R. Engel, C. Correll, and J.M. Kane. 2003. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory metaanalysis of randomized, controlled trials. American Journal of Psychiatry 160: 1209-1222. (Pubitemid 41070936)
23. Leucht, S.; M. Tardy, K. Komossa, S. Heres, W. Kissling, G. Salanti, and J.M. Davis. 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet 379: 2063-2071.
24. Leysen, J.E.; W. Gommeren, A. Eens, D. de Chaffoy de Courcelles, J.C. Stoof, and P.A. Janssen. 1988. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 247: 661-670.
25. Lindenmayer, J.P. 2010. Long-acting injectable antipsychotics: Focus on olanzapine pamoate. Journal of Neuropsychiatric Disease and Treatment 6: 261-267.
26. Luo, J.P.; J.W. Hubbard, and K.K. Midha. 1997. Studies on the mechanism of absorption of depot neuroleptics: Fluphenazine decanoate in sesame oil. Pharmaceutical Research 14: 1079-1084. (Pubitemid 27371410)
27. Maulding, H.V.; T.R. Tice, D.R. Cowsar, J.W. Fong, J.E. Pearson, and J.P. Nazareno. 1986. Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament. Journal of Controlled Release 3: 103-117. (Pubitemid 16168144)
28. Naber, D. 2011. Olanzapine pamoate for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 12: 627-633.
29. Naheed, M.; and B. Green. 2001. Focus on clozapine. Current Medical Research and Opinion 17: 223-229. (Pubitemid 34003125)
30. Park, E.J.; T.H. Tak, D.H. Na, and K.C. Lee. 2010. Effect of PEGylation on stability of peptide in poly(lactide-co-glycolide) microspheres. Archives of Pharmacal Research 33: 1111-1116.
31. Rawat, A.; E. Stippler, V.P. Shah, and D.J. Burgess. 2011. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta. International Journal of Pharmaceutics 420: 198-205.
32. Rawat, A.; U. Bhardwaj, and D.J. Burgess. 2012. Comparison of in vitro-in vivo release of Risperdal Consta microspheres. International Journal of Pharmaceutics 434: 115-121.
33. Risbood, V.; J.R. Lee, J. Roche-Desilets, and M.A. Fuller. 2012. Lurasidone: An atypical antipsychotic for schizophrenia. Annals of Pharmacotherapy 46: 1033-1046.
34. Rössler, W.; H.J. Salize, J. van Os, and A. Riecher-Rössler. 2005. Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology 15: 399-409. (Pubitemid 40943544)
35. Rubio, M.D.; J.B. Drummond, and J.H. Meador-Woodruff. 2012. Glutamate receptor abnormalities in schizophrenia: Implications for innovative treatments. Biomolecules & Therapeutics 20: 1-18.
36. Samtani, M.N.; A. Vermeulen, and K. Stuyckens. 2009. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: A novel once-monthly, long-acting formulation of an atypical antipsychotic. Clinical Pharmacokinetics 48: 585-600.
37. Sedky, K.; R. Nazir, J.P. Lindenmayer, and S. Lippman. 2010. Paliperidone palmitate: Once monthly treatment option for schizophrenia. Current Psychiatry Online 9: 48-50.
38. Selmin, F.; P. Blasi, and P. P. Deluca. 2012. Accelerated polymer biodegradation of risperidone poly(d,l-lactide-co-glycolide) microspheres. AAPS Pharm Sci Tech 13: 1465-1472.
39. Serajuddin, A.T. 2007. Salt formation to improve drug solubility. Advanced Drug Delivery Reviews 59: 603-616. (Pubitemid 47285406)
40. Shen, W.W. 1999. A history of antipsychotic drug development. Comprehensive Psychiatry 40: 407-414.
41. Shive, M.S.; and J.M. Anderson. 1997. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 28: 5-24. (Pubitemid 27497671)
42. Su, Z.; F. Sun, Y. Shi, C. Jiang, Q. Meng, L. Teng, and Y. Li. 2009. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(d,l-lactide-co-glycolide) microsphere. Chemical & Pharmaceutical Bulletin 57: 1251-1256.
43. Su, Z.X.; Y.N. Shi, L.S. Teng, X. Li, L.X. Wang, Q.F. Meng, L.R. Teng, and Y.X. Li. 2011. Biodegradable poly(d,l-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Pharmaceutical Development and Technology 16: 377-384.
44. Tandon, R.; and M.D. Jibson. 2002. Extrapyramidal side effects of antipsychotic treatment: Scope of problem and impact on outcome. Annals of Clinical Psychiatry 14: 123-129. (Pubitemid 35006794)
45. Taylor, D. 2009. Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. British Journal of Psychiatry 52: S13-S19.
46. Valenstein, M.; L.A. Copeland, R. Owen, F.C. Blow, and S. Visnic. 2001. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Journal of Clinical Psychiatry 62: 545-551. (Pubitemid 32703095)
47. Wischke, C.; and S.P. Schwendeman. 2008. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. International Journal of Pharmaceutics 364: 298-327.
48. Zuardi, A.W.; A.C. Giampietro, and E.R. Grassi. 1983. Double-blind comparison between two forms of haloperidol: An oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients. Current Therapeutic Research 34: 253-261. (Pubitemid 15125646)